In the last trading session, 1.43 million Heron Therapeutics Inc (NASDAQ:HRTX) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $1.68 changed hands at -$0.09 or -5.08% during last session, the market valuation stood at $255.52M. HRTX’s last price was a discount, traded about -133.93% off its 52-week high of $3.93. The share price had its 52-week low at $1.04, which suggests the last value was 38.1% up since then.
Analysts gave the Heron Therapeutics Inc (HRTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HRTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Heron Therapeutics Inc’s EPS for the current quarter is expected to be -0.03.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX was in red as seen at the end of in last trading. With action -2.33%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 9.80%, with the 5-day performance at -2.33% in the red. However, in the 30-day time frame, Heron Therapeutics Inc (NASDAQ:HRTX) is -8.20% down.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 76.0% from its current market value. According to analyst projections, HRTX’s forecast low is 5 with 9 as the target high. To hit the forecast high, the stock’s price needs a -435.71% plunge from its current level, while the stock would need to soar -197.62% for it to hit the projected low.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Year-over-year growth is forecast to reach 10.88% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 37.37M. 1 analysts are of the opinion that Heron Therapeutics Inc’s revenue for the current quarter will be 34.25M. The company’s revenue for the corresponding quarters a year ago was 34.23M and 34.67M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 9.15%. The estimates for the next quarter sales put growth at -1.21%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.01%. The 2025 estimates are for Heron Therapeutics Inc earnings to increase by 83.89%.
HRTX Dividends
Heron Therapeutics Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 4.68 shares estimated at $7.87 million under it, the former controlled 3.08% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.17% of the shares, roughly 3.29 shares worth around $5.54 million.
